April 2013

Contents

Editorial

• Volume 14 Number 3/4 March/April 2013

Conference reports

• 20th Conference on Retroviruses and Opportunistic Infections (CROI) 3-6 March 2013, Atlanta

• ARV pipeline: dolutegravir, TAF (GS-7340), MK-1439 and cenicriviroc

• ARV pipeline: long-acting formulations of rilpivirine, GSK-744 and nanoformulations

• Five-year results from the AntiRetroviral Research for Watoto (ARROW) Trial

• Comparison of ritonavir-boosted lopinavir or NNRTI ART and PK with antimalarials in Ugandan children

• Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years

• Pharmacokinetics of currently available antiretroviral options for young children

• Safety of transplacental raltegravir in neonates and washout pharmacokinetics

• Tenofovir use in children

• ddI resistance in South African children failing an abacavir or d4T based first-line regimen

• Statin use in HIV positive people

• RIFAQUIN study demonstrates once-weekly dosing during follow-up phase of TB treatment

• Combining Xpert and LAM urine testing improves TB diagnostic sensitivity

• Deferring ART by four weeks reduces mortality in patients diagnosed with cryptococcal meningitis

• Monthly injection protects macaques from rectal exposure: results should fast-track human studies for advanced PrEP options

• Tenofovir DF ring protects macaques from vaginal exposure

• VOICE study reports low adherence as reason for lack of efficacy for PrEP: anal sex common in African heterosexuals

• Further studies on how male circumcision may reduce HIV transmission

• Report of a functional cure in an HIV infected infant

Antiretrovirals

• Dietary requirements changed in Europe for fixed dose combination rilpivirine/tenofovir/FTC (Eviplera)

• EU adopts positive opinion for decision on regulatory approval of Quad

• Gilead Sciences announces fourth quarter and full year 2012 financial results

• ViiV stops development of NNRTI lersivirine

• Nelfinavir non-renewal of marketing authorisation in the EU

• START study increases sample size: additional 600 participants to be older than 35

Treatment strategies

• Why the “when to start” question is complex and informed by limited evidence: a response to Dr Myron Cohen

Paediatric care

• Once-daily option for paediatric use of darunavir/ritonavir

Guidelines

• US (DHHS) ARV guidelines updated (February 2013): moderate recommendation to treat at CD4 count >500 is based only on expert opinion

Side effects

• No impact of ART on progression or regression of anal squamous intraepithelial lesions

• Osteonecrosis in HIV positive patients is associated with increased levels of CRP and D-dimer

• Cognitive disorders are common in French cohort but are not HIV-related

TB coinfection

• Tuberculosis MVA85A vaccine trial shows lack of efficacy in infants

Basic science and immunology

• CD4 T cells specific for different pathogens vary in susceptibility to HIV infection

Other news

• US Senate supports bill to allow HIV positive organ donations to HIV positive recipients

• Update on AllTrials campaign for publication of full research results: PhRMA unhappy but GSK sign up

PDFs

• Volume 14 Number 3/4 March/April 2013 PDF